Keap1在非小细胞肺癌中的表达及与化疗疗效相关性的研究

背景与目的已有研究表明Kelch样环氧氯丙烷相关蛋白1（Kelch-like ECH-associated protein1,Keap1）与铂类耐药相关。本研究旨在探讨Keap1在进展期非小细胞肺癌（non-small cell lung cancer,NSCLC）中的表达及其与一线含铂化疗方案疗效的相关性。方法应用免疫组化检测50例进展期NSCLC患者组织标本中Keap1的表达。结果进展期NSCLC患者中Keap1高表达率为26.0%;Keap1表达水平与化疗疗效、无进展生存期（progression free survival,PFS）有关（P〈0.05）,而与性别、年龄、吸烟、病理类型、...

Full description

Saved in:
Bibliographic Details
Published in中国肺癌杂志 Vol. 15; no. 10; pp. 591 - 596
Main Author 曹宝山 朱翔 陈森 肖宇 梁莉
Format Journal Article
LanguageChinese
Published 北京大学第三医院肿瘤治疗中心化疗与放射病科,北京,100191%北京大学第三医院肿瘤治疗中心病理科,北京,100191 2012
Subjects
Keapl
化疗
无进展生存期
肺肿瘤
Keap1
无进展生存期
化疗
肺肿瘤
Online AccessGet full text
ISSN1009-3419
1999-6187
DOI10.3779/j.issn.1009-3419.2012.10.05

Cover

More Information
Summary:背景与目的已有研究表明Kelch样环氧氯丙烷相关蛋白1（Kelch-like ECH-associated protein1,Keap1）与铂类耐药相关。本研究旨在探讨Keap1在进展期非小细胞肺癌（non-small cell lung cancer,NSCLC）中的表达及其与一线含铂化疗方案疗效的相关性。方法应用免疫组化检测50例进展期NSCLC患者组织标本中Keap1的表达。结果进展期NSCLC患者中Keap1高表达率为26.0%;Keap1表达水平与化疗疗效、无进展生存期（progression free survival,PFS）有关（P〈0.05）,而与性别、年龄、吸烟、病理类型、分化程度、转移和总生存期无关（P〉0.05）。Keap1高表达组的中位PFS明显高于低表达组（P=0.002）。多因素分析表明Keap1表达水平是一线化疗方案PFS的独立预测因素（P=0.007）。结论 Keap1与进展期NSCLC一线化疗疗效和PFS有关,Keap1可能成为新的化疗疗效预测指标。
Bibliography:Baoshan CAO, Xiang ZHU, Sen CHEN, Yu XIAO, Li LIANG （1.Department of Oncology and Radiation Sickness, Cancer Center; 2Department of Pathology, Peking University Third Hospital, Beijing i 00191, China）
Background and objective It has been proven that Kelch-like ECH-associated protein 1 （Keapl） expression was correlated with the chemoresistance of platinum drugs. The aim of this study is to investigate the protein expres- sion levels of Keapl in non-small cell lung cancer （NSCLC） patients as well as to correlate its expression with the response rate （RR）, progression-free survival （PFS）, and overall survival （OS） of patients treated with platinum-based first-line chemother- apy. Methods The immunohistochemical analysis of Keapl expression was performed using tumor samples from 50 patients with stage III or IV NSCLC. Results The high expression ratio of Keapl was 26.0%. The Keap1 expression was significantly correlated with the RR and PFS after platinum-based chemotherapy （P〈0.05） but not with the gender, age, sm
ISSN:1009-3419
1999-6187
DOI:10.3779/j.issn.1009-3419.2012.10.05